





SETTA	TRACE		<u></u>
Atty. Docket No.	08702.0009-01000	Appln. No. 09/512,701	TECH 2 8 2003
Applicant	LEONARD et al.		CENTED.
Filing Date	February 25, 2000	Group: 1645	

		U.S. PATENT	DOCUMENTS			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Dat If Appropriat
MM	5,536,657	16 Jul. 1996	Chua et al.	1	1	
M	5,650,492	22 Jul. 1997	Gately et al.			
Mu.	5,840,530	24 Nov. 1998	Gubler et al.			
1////	5,852,176	22 Dec. 1998	Gubler et al.			
m	5,853,721	29 Dec. 1998	Gately et al.	\	5	
	5,955,476	21 Sep. 1999	Muller et al.			
MM	5,969,102	19 Oct. 1999	Bram et al.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
MM	6,054,487	25 Apr. 2000	Sekut et al.			
MM	6,225,117 B1	1 May 2001	Gately et al.		4	
MM	6,258,562 B1	10 Jul. 2001	Salfeld et al.			
MM	6,338,848 B1	15 Jan. 2002	Leonard et al.		-	

		FOREIGN PATEN	IT DOCUMENT	S		
	Document Number	Publication Date	Country	Class	Sub Class	Translati n Yes or N
	WO 92/05256	02 Apr. 1992	WIPO	/		***
MM.	WO 93/19770	14 Oct. 1993	WIPO		7	
W	WO 98/16248	23 Apr. 1998	WIPO	1		
MM	WO 98/22137	28 May 1998	WIPO			
M	WO 98/41232	24 Sep. 1998	WIPO			
	WO 99/36073	22 Jul. 1999	WIPO	 		
7////	WO 99/37682	29 Jul. 1999	WIPO			
1/1//	0 433 827 A2	26 Jun. 1991	EPO	1		

MM Minnfield

7/7/03







Atty. Docket No.	08702.0009-01000	Appln. No.	09/512,701	7504 a = 2 8 2003
Applicant	LEONARD et al.			CENTER 1600/2000
Filing Date	February 25, 2000	Group:	1645	300/2300

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Arnaudova et al., Application of Interferon- γ Containing Gel for Local Treatment of Skin Ulcers in Autoimmune Vasculitides and Skin Changes in Progressive Systemic Sclerosis, <i>The Journal of Rheumatology</i> , 20:1445-1446 (1993).
Tun	Bach, Immunosuppressive Therapy of Autoimmune Diseases, <i>Immunology Today</i> , 14:322-326 (1993).
m	Bach, Immunosuppressive Therapy of Autoimmune Diseases, <i>Trends in Pharmacological Sciences</i> , 14:213-216 (1993).
mm	Balashov et al., Increased Interleukin 12 Production in Progressive Multiple Sclerosis: Induction by Activated CD4 ⁺ T Cells Via CD40 Ligand, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 94:599-603 (1997).
	Bankhurst, Interferons and Systemic Lupus Erythematosus, <i>Journal of Rheumatology</i> , 14:63-67 (1987).
	Baron et al., Production of Tumor Necrosis Factor and Other Proinflammatory Cytokines by Human Mononuclear Phagocytes Stimulated with Myelin P2 Protein, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 90,4414-4418 (1993).
YM	Baron et al., Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma, <i>Journal of Experimental Medicine</i> , 177:57-68 (1993).
m	Butler et al., Anti-IL-12 and Anti-TNF Antibodies Synergistically Suppress the Progression of Murine Collagen-Induced Arthritis, <i>European Journal of Immunology</i> , 29:2205-2212 (1999).
	Campbell et al., Essential Role for Interferon-γ and Interleukin-6 in Autoimmune Insulin-Dependent Diabetes in NOD/Wehi Mice, <i>Journal of Clinical Investigation</i> , 87:739-742 (1991).
	Castaño et al., Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat, Annual Review of Immunology, 8:647-679 (1990).
	Chan et al., Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers, <i>Journal of Experimental Medicine</i> , 173:869-879 (1991).
m**	Charteris et al., Interferon-Gamma (IFN- γ) Production <i>In Vivo</i> in Experimental Autoimmune Uveoretinitis, <i>Immunology</i> , 75:463-467 (1992).
M	Chizzonite et al., IL-12 Receptor. I. Characterization of the Receptor on Phytohemagglutinin-Activated Human Lymphoblasts, <i>The Journal of Immunology</i> , 148:3117-3124 (1992).
m	Chizzonite et al., IL-12: Monoclonal Antibodies Specific for the 40-kDa Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts, <i>The Journal of Immunology</i> , 147:1548-1556 (1991).
M	Chofflon et al., Tumor Necrosis Factor α Production as a Possible Predictor of Relapse in Patients with Multiple Sclerosis, <i>European Cytokine Network</i> , 3:523-531 (1992).

MM Monnyfild 7/7/03

Page 2 of 6







	Ott 4 70 800		FFD JU
Atty. Docket No	08702.0009-01000	Appln. No. 09/512,	701 /ECH 2 8 2003
Applicant	LEONARD et al.		SENTER 100
Filing Date	February 25, 2000	Group: 1645	1, 1990/2900

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MM	Chua et al., Expression Cloning of a Human IL-12 Receptor Component: A New Member of the Cytokine Receptor Superfamily with Strong Homology to gp130, <i>The Journal of Immunology</i> , 153:128-136 (1994).
	Constantinescu et al., IL-12 Reverses the Suppressive Effect of the CD40 Ligand Blockade on Experimental Autoimmune Encephalomyelitis (EAE), <i>Journal of the Neurological Sciences</i> , 171:60 64 (1999).
	Deguchi et al., Tumour Necrosis Factor/Cachectin Plays a Key Role in Autoimmune Pulmonary Inflammation in Lupus-Prone Mice, Clinical and Experimental Immunology, 85:392-395 (1991).
	Duchmann et al., Interleukin-12 mRNA is Induced in Lamina Propria Mononuclear Cells from Patients with Inflammatory Bowel Disease (IBD), Gastroenterology (Suppl.), 104:A693 (1993).
mu	Feldmann et al., Evaluation of the Role of Cytokines in Autoimmune Disease: The Importance of TNF α in Rheumatoid Arthritis, <i>Progress in Growth Factor Research</i> , 4:247-255 (1992).
mu mm	Fox et al., Anti-Interleukin-12 Antibody: Potential Role in Preventing Relapses of Multiple Sclerosis, <i>BioDrugs</i> , 13:233-241 (2000).
JM	Fujihira et al., Suppression and Acceleration of Autoimmune Diabetes by Neutralization of Endogenous Interleukin-12 in NOD Mice, <i>Diabetes</i> , 49:1998-2006 (2000).
	Funauchi et al., Serum Level of Interferon-γ in Autoimmune Diseases, <i>Tohoku Journal of Experimental Medicine</i> , 164:259-267 (1991).
mu	Gately et al., Interleukin-12 Antagonist Activity of Mouse Interleukin-12 p40 Homodimer in Vitro and in Vivo, Annals New York Academy of Sciences, 795:1-12 (1996).
	Germann et al., IL-12, a Cytokine with Multiple Effects on T _H 1-, but not on T _H 2-cells, <i>Immunobiology</i> , 186:38 (1992).
	Godfrey et al., A Developmental Pathway Involving Four Phenotypically and Functionally Distinct Subsets of CD3 ⁻ CD4 ⁻ CD8 ⁻ Triple-Negative Adult Mouse Thymocytes Defined by CD44 and CD25 Expression, <i>The Journal of Immunology</i> , 150:4244-4252 (1993).
M	Greig et al., A Comparison of the Effects of Melengestrol Acetate and Hydrocortisone Acetate on Experimental Allergic Encephalomyelitis in Rats, <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 173:85-93 (1970).
	Harris, et al., Therapeutic Antibodies - The Coming of Age, <i>Trends in Biotechnology</i> , 11:42-44 (1993).
M	Heremans et al., Role of Endogenous Interleukin-12 (IL-12) in Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis in Mice, <i>European Cytokine Network</i> , 10:171-179 (1999).
m	Higgins et al., Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myèlin Basic Protein and Its Fragments, <i>The Journal of Immunology</i> , 140:440-445 (1988).
m	Hofman et al., Immunoregulatory Molecules and IL 2 Receptors Identified in Multiple Sclerosis Brain, <i>The Journal of Immunology</i> , 136:3239-3245 (1986).

Page 3 of 6

MM Minnifield 7/7/03







Atty. Docket N	lo. 08702.0009-01000	Appln. No.	09/512,701	TECU - 2 8 2003
Applicant	LEONARD et al.			JULY CENTER 1600/2000
Filing Date	February 25, 2000	Group:	1645	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
M	Hofman et al., Lymphokines and Immunoregulatory Molecules in Subacute Sclerosing Panencephalitis, <i>Clinical Immunology and Immunopathology</i> , 58:331-342 (1991).
M	Hofman et al., Tumor Necrosis Factor Identified in Multiple Sclerosis Brain, <i>Journal of Experimental Medicine</i> , 170:607-612 (1989).
MM	Hunter et al., Immunoregulation by Interleukin-12 in MB49.1 Tumor-Bearing Mice: Cellular and Cytokine-Mediated Effector Mechanisms, <i>European Journal of Immunology</i> , 27:3438-3446 (1997).
MM	Ichikawa et al., Anti-IL-12 Antibody Prevents the Development and Progression of Multiple Sclerosis-Like Relapsing-Remitting Demyelinating Disease in NOD Mice Induced with Myelin Oligodendrocyte Glycoprotein Peptide, <i>Journal of Neuroimmunology</i> , 102:56-66 (2000).
·mm	Jaffe, Combination Therapy of Rheumatoid Arthritis—Rationale and Overview, <i>Journal of Rheumatology</i> , 17 (supplement 25): 24-27 (1990).
MM	Joosten et al., Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra, <i>Annals of Rheumatic Diseases</i> , 59(3): 196-205 (2000).
	Karlsson et al., Autoimmune Endocrinopathies 5: Autoimmune Disease of the Adrenal Cortex, Pituitary, Parathyroid Glands and Gastric Mucosa, <i>Journal of Internal Medicine</i> , 234:379-386 (1993).
m	Kim et al., The role of IL-12 in Inflammatory Activity of Patients with Rheumatoid Arthritis (RA), Clinical and Experimental Immunology, 119:175-181 (2000).
	Kobayashi et al., Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes, <i>Journal of Experimental Medicine</i> , 170:827-845 (1989).
m	Lagoo et al., Proinflammatory Cytokine Production by Rheumatoid Arthritis Synovial Fibroblasts, Journal of Cellular Biochemistry (Suppl. O), 17:146 (1993).
MM	Leonard et al., Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon-γ Production, <i>Blood</i> , 90:2541-2548 (1997).
m	Leonard et al., Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12, <i>Journal of Experimental Medicine</i> , 181:381-386 (1995).
M	Leonard et al., Regulation of Experimental Autoimmune Encephalomyelitis by Interleukin-12, Annals New York Academy of Sciences, 795:216-226 (1996).
	Leonard et al., Regulation of the Inflammatory Response in Animal Models of Multiple Sclerosis by Interleukin-12, <i>Critical Reviews in Immunology</i> , 17:545-553 (1997).
	Lernmark et al., Autoimmune Endocrinopathies 3: Islet Cell Autoimmunity, <i>Journal of Internal Medicine</i> , 234:361-369 (1993).
M	Malfait et al., Blockade of IL-12 During the Induction of Collagen-Induced Arthritis (CIA) Markedly Attenuates the Severity of the Arthritis, <i>Clinical and Experimental Immunology</i> , 111:377-383 (1998).

Page 4 of 6

NM Hynnifield 7/7/63







OMB NE/ 1027-0011

FEB 28 2003

	lo. 08702.0009-01000	Appln. No.	09/512,701	IECH CENTER
Applicant	LEONARD et al.			CIVIEH 1600/2900
Filing Date	February 25, 2000	Group:	1645	

	<u></u>					
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
M	Manetti et al., Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-Producing Th Cells., <i>Journal of Experimental Medicine</i> , 177:1199-1204 (1993).					
m	Merrill et al., Inflammatory Leukocytes and Cytokines in the Peptide-Induced Disease of Experimental Allergic Encephalomyelitis in SJL and B10.PL Mice, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 89:574-578 (1992).					
17/1	Merrill et al., T Cell Lines Established from Multiple Sclerosis Cerebrospinal Fluid T cells Using Human Retroviruses, <i>Journal of Neuroimmunology</i> , 21:213-226 (1989).					
M	Panitch et al., Treatment of Multiple Sclerosis with Gamma Interferon: Exacerbations Associated with Activation of the Immune System, <i>Neurology</i> , 37:1097-1102 (1987).					
M	Peeva et al., Rheumatoid Arthritis Exacerbation Caused by Exogenous Interleukin-12, Arthritis & Rheumatism, 43:461-463 (2000).					
MM	Rothe et al., Suppression of Cyclophosphamide Induced Diabetes Development and Pancreatic Th1 Reactivity in NOD Mice Treated with the Interleukin (IL)-12 Antagonist IL-12(p40) ₂ , <i>Diabetologia</i> , 40:641-646 (1997).					
Saito et al., Effect of CD80 and CD86 Blockade and Anti-Interleukin-12 Treatment on Mouse Graft-Versus-Host Disease, European Journal of Immunology, 26:3098-3106 (1996).						
	Serreze, Autoimmune diabetes results from genetic defects manifest by antigen presenting cells, FASEB Journal, 7:1092-1096 (1993).					
m	Simon et al., Divergent T-cell Cytokine Patterns in Inflammatory Arthritis, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 91:8562-8566 (1994).					
m	Smith et al., Interleukin-12 Induces Relapse in Experimental Allergic Encephalomyelitis in the Lewis Rat, <i>American Journal of Pathology</i> , 150:1909-1917 (1997).					
	Smith et al., The Role of T Cells in Myosin-Induced Autoimmune Myocarditis, <i>Clinical Immunology and Immunopathology</i> , 68:100-106 (1993).					
M	Steinman, Autoimmune Disease: Misguided Assaults on the Self Produce Multiple Sclerosis, Juvenile Diabetes and Other Chronic Illnesses: Promising Therapies are Emerging, <i>Scientific American</i> , September:107-114 (1993).					
	Tang, et al., The Effects of a Monoclonal Antibody to Interferon-γ on Experimental Autoimmune Thyroiditis (EAT): Prevention of Disease and Decrease of EAT-Specific T Cells, <i>European Journal of Immunology</i> , 23:275-278 (1993).					
MM	Trinchieri et al., Natural Killer Cell Stimulatory Factor (NKSF) or Interleukin-12 is a Key Regulator of Immune Response and Inflammation, <i>Progress in Growth Factor Research</i> , 4:355-368 (1992).					
MM	Van der Veen et al., The Effect of Methylprednisone Pulse Therapy on Methyltrexate Treatment of Rheumatoid Arthritis, Clinical Rheumatology, 12:500-505 (1993).					
WM	Veys et al., Interferon Gamma in Rheumatoid Arthritis - A Double Blind Study Comparing Human Recombinant Interferon Gamma with Placebo, <i>The Journal of Rheumatology</i> , 15:570-574 (1988).					
MM MM MM	Trinchieri et al., Natural Killer Cell Stimulatory Factor (NKSF) or Interleukin-12 is a Key Regulator of Immune Response and Inflammation, <i>Progress in Growth Factor Research</i> , 4:355-368 (1992). Van der Veen et al., The Effect of Methylprednisone Pulse Therapy on Methyltrexate Treatment of Rheumatoid Arthritis, <i>Clinical Rheumatology</i> , 12:500-505 (1993). Veys et al., Interferon Gamma in Rheumatoid Arthritis - A Double Blind Study Comparing Human					

Page 5 of 6

NM Herinifield 7/7/03







_		10 AU			
	Atty. Docket No.	08702.0009-01000	Appln. No.	09/512,701	TECH 0 2003
	Applicant	LEONARD et al.			CENTER 1600/pc
	Filing Date	February 25, 2000	Group:	1645	1000/2910

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	Via et al., IL12 Prevents Autoimmunity in a Murine Model of SLE., <i>Arthritis and Rheumatism</i> , 36:148 (1993).				
my	Vitali, et al., Immunotherapy in Rheumatoid Arthritis, <i>The International Journal of Artificial Organs</i> , 16:196-200 (1993).				
MM	Waldburger et al., Adoptive Transfer of Experimental Allergic Encephalomyelitis After in Vitro Treatment with Recombinant Murine Interleukin-12, American Journal of Pathology, 148:375-382 (1996).				
M	Wilske, Approaches to the Management of Rheumatoid Arthritis: Rationale for Early Combination Therapy, <i>British Journal of Rheumatology</i> , 32 (supplement 1) 24-27 (1993).				

Examiner Date Considered

*Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011 #23

				
Atty. Docket No.	08702.0009-01000	Serial No. 09	9/512,701	
Applicant	LEONARD et al.			
Filing Date	February 25, 2000	Group: 16	645	

		FOREIGN PATE	ENT DOCUMENTS	3						
	Document Number	Publication Date	Country	Clas	1	Sub Class	English Language Translation Yes or No			
MM	0 625 354 A1	11/23/94	EPO			1	Yes-Abstract only			
m	0 638 644 A1	2/15/95	EPO							
m	0 640 689 A2	3/1/95	EPO							
MM	2,123,049	11/8/1994	Canada							
				•		1				
	OTHER DOCUMEN	ITS (Including Au	thor, Title, Date, I	Pertine	nt Pa	ges, Etc	:.)			
M		Becher et al., "Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12," Jour. Clin. Invest., 110(4):493-497 (2002).								
M		Benson et al., "The role of IL-23 in experimental autoimmune encephalomyelitis," FASEB Journal, 16(5):A1045 (2002).								
M		Fuss et al., "Disparate CD4 ⁺ lamina propria (LP) lumphokine secretion profiles in inflammatory bowel disease," <i>The Journal of Immunology</i> , 57(3):1261-1270 (1996).								
my		Germann et al., "Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice," Proc. Natl. Acad. Sci. USA, 92:4823-4827 (1995).								
M	encephalomyelitis:	Gran et al., "IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination," The Journal of Immunology, 169(12):7104-7110 (2002).								
m		Mattner et al., "The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer," Eur. J. Immunol., 23:2202-2208 (1993).								
MM		Romagnani, S., "Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology," <i>Int. Arch. Allergy Immunol.</i> 98:279-285 (1992).								
m	Via et al., "IL-12 sti normally would dev Immunology, 153(\$	elop chronic, auto	immune graft-vers	aft-vers us-hos	sus-ho t disea	st disea ase," <i>The</i>	se in mice that e <i>Journal of</i>			
Examiner /	Mitter	ndield	Date Considered		7-	7-0	23			
. th	nitial if reference consideration if not in ommunication to applic	lered, whether or n conformance and r								
Form PTO 1449		Patent and	Trademark Of	fice - I	U.S. 1	Depart	ment of Commerc			